Joseph Lee, MD
Clinical Cardiac Electrophysiology · Bethesda, MDNPI 1922098201
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Medtronic at 56.1% of the total. Reporting peaked in 2022 at $9,609 and has fallen 66.8% since, to $3,194 in 2025.
Across 228 payments — averaging $85.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$11K
- Abbott$2K
- E.r. Squibb & Sons, L.L.C.$633
- Cvrx, Inc.$528
- Johnson & Johnson$519
- Novartis$407
- plus $4K from 28 others
What the payments were for
- Consulting fees$3002%
- Speaking & faculty fees$6,67534%
- Travel & lodging$3,16116%
- Food & beverage$9,43648%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 49 | $10,984 |
| Abbott | 27 | $2,167 |
| E.r. Squibb & Sons, L.L.C. | 14 | $633 |
| Cvrx, Inc. | 6 | $528 |
| Johnson & Johnson | 10 | $519 |
| Novartis | 12 | $407 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $376 |
| Boston Scientific | 10 | $362 |
| Novo Nordisk | 7 | $325 |
| Scpharmaceuticals Inc. | 9 | $293 |
| Sanofi-aventis U.S. LLC | 10 | $282 |
| Kestra Medical Technology Services, Inc. | 4 | $260 |
| Heartflow, Inc. | 3 | $228 |
| Pfizer | 14 | $226 |
| Biosense Webster, Inc. | 5 | $200 |
| Boehringer Ingelheim | 4 | $172 |
| Atricure, Inc. | 2 | $152 |
| Bridgebio Pharma, Inc. | 1 | $144 |
| ZOLL Respicardia, Inc. | 1 | $136 |
| Amarin Pharma, Inc. | 1 | $125 |
| Lilly USA, LLC | 1 | $125 |
| Ionis Pharmaceuticals, Inc. | 1 | $122 |
| Bayer | 1 | $119 |
| Cardiva Medical, Inc. | 1 | $119 |
| Esperion Therapeutics, Inc. | 2 | $116 |
| Lexicon Pharmaceuticals, Inc. | 3 | $83 |
| Amgen | 5 | $78 |
| Philips North America LLC | 2 | $72 |
| Baxter Healthcare | 2 | $66 |
| Merck | 3 | $62 |
| Recor Medical Inc | 1 | $28 |
| Abiomed | 1 | $23 |
| AstraZeneca | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$1,059
- Micra$721
- EVERA MRI XT DR SURESCAN$558
- Barostim Neo System$415
- CAMZYOS$365
- CardioInsight$300
- AZURE XT DR MRI SURESCAN$256
- XARELTO$250
- ENSITE$243
- FFRct$226
- CardioMEMS HF System$147
- Attruby$144
- remede System$136
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$134
- JOT DX$130
- Vascepa$125
- TRYNGOLZA$122
- FUROSCIX$122
- PRALUENT$121
- Kerendia$119
How this compares
$19,572 in reported general payments places this provider in the 55th percentile of 63 clinical cardiac electrophysiology providers in Maryland.
See all clinical cardiac electrophysiology providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 367 | $506,866 |
| XareltoRivaroxaban | 69 | $93,560 |
| EntrestoSacubitril/Valsartan | 27 | $43,346 |
| MultaqDronedarone Hcl | 16 | $31,830 |
| Dofetilide | 79 | $19,898 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 30 | $6,278 |
| Diltiazem 12hr ErDiltiazem Hcl | 21 | $4,966 |
| Amiodarone Hcl | 174 | $4,464 |
| Metoprolol Succinate | 290 | $4,187 |
| Flecainide Acetate | 76 | $2,325 |
| Digoxin | 23 | $831 |
| Midodrine Hcl | 18 | $824 |
| Atorvastatin Calcium | 78 | $753 |
| Rosuvastatin Calcium | 42 | $639 |
| Carvedilol | 47 | $413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $226 | $506,866367 claims |
| Johnson & JohnsonXarelto | $519 | $93,56069 claims |
| NovartisEntresto | $407 | $43,34627 claims |
| Sanofi-aventis U.S. LLCMultaq | $282 | $31,83016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 63 clinical cardiac electrophysiology providers in Maryland.
Other clinical cardiac electrophysiology in Bethesda
- Cicely DyeBethesda$54K
- Edward HealyBethesda$8K
- Brian PomerantzBethesda$8K
- Matthew NeedlemanBethesda$7K
- Sean BeinartRockville$315K
- Charles LoveBaltimore$238K
- Hugh CalkinsBaltimore$202K
- Paresh ShahBaltimore$97K
- Helen BaroldRockville$83K
- Jonathan ChrispinBaltimore$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.